Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
HI-Bio: A Biogen Company logo — HI-Bio is a clinical-stage biotech company delivering target...

HI-Bio: A Biogen Company

HI-Bio is a clinical-stage biotech company delivering targeted therapies for patients with immune-mediated diseases.

Founded 2021 United States South San Francisco, United States 22 employees Acquired Total: $1.37B Biotechnology, Health and Wellness +1

General Information

Company Name HI-Bio: A Biogen Company
Founded Year 2021
Location United States South San Francisco, United States
Employees 22
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Acquired
Business Model B2B, B2D, B2B2C
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with HI-Bio: A Biogen Company. To contact HI-Bio: A Biogen Company, visit hibio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does HI-Bio: A Biogen Company compare?

A PDF of HI-Bio: A Biogen Company and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting HI-Bio: A Biogen Company soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About HI-Bio: A Biogen Company

HI-Bio, a clinical-stage biotech company, has made a notable impact in the realm of biotechnology since its founding in 2021. The company's focus on delivering targeted therapies for patients with immune-mediated diseases aligns with its mission to innovate in the Biotechnology, Health and Wellness, and Life Sciences industries.

Recently, HI-Bio garnered attention with its acquisition by Biogen on 01 May 2024. This significant step involved a $1.15 billion acquisition investment from Biogen Idec New Ventures, reflecting confidence in the startup's promising pipeline and strategic alignment with Biogen's existing portfolio.

Operating from its headquarters in the United States, HI-Bio's integration into Biogen marks a pivotal moment, promising to accelerate the development and delivery of innovative treatments. This strategic acquisition underscores the robust potential and impactful contributions of HI-Bio to the biotechnology field.

Business keywords: immune-mediated diseases, targeted therapies, clinical-stage, felzartamab, anti-CD38 monoclonal antibody, immune cell depletion, plasma cells, natural killer cells, immunology, therapeutics development, clinical outcomes, biopharmaceuticals, antibody therapies

Services & Products

Research and Development
Clinical Trials
Medicine Manufacturing
Early Access Programs
Healthcare Innovation

Target Customers

Medical Professionals Patients Researchers Investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $1.15B 1
Biogen Idec New Ventures
Biogen Idec New Ventures
01 May 2024
Series B $95.00M 5
Arch Venture Partners Alpha Wave Global Jeito Capital
Arch Venture Partners, Alpha Wave Global +3
01 Jan 2024
Early VC $120.00M 3
Arch Venture Partners Jeito Capital Monograph Capital
Arch Venture Partners, Jeito Capital +1
01 Nov 2022

HI-Bio: A Biogen Company Alternatives & Competitors

View All Alternatives
HI-Bio: A Biogen Company vs
Connect Biopharma
Connect Biopharma United States

Global Clinical Stage Company Connecting Patients with Innovation for Life

Series C
30 employees
Biotechnology, Health Care
HI-Bio: A Biogen Company vs
Alumis
Alumis United States

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Series C
249 employees
Biotechnology, Health Care
HI-Bio: A Biogen Company vs
Upstream Bio
Upstream Bio United States

Developing treatments for inflammatory diseases

IPO
78 employees
Biotechnology, Health Care
View all alternatives

FAQ About HI-Bio: A Biogen Company

HI-Bio is a clinical-stage biotech company delivering targeted therapies for patients with immune-mediated diseases.
HI-Bio: A Biogen Company was founded in 2021.
HI-Bio: A Biogen Company is headquartered in South San Francisco, United States.
HI-Bio: A Biogen Company operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on immune-mediated diseases, targeted therapies, clinical-stage and felzartamab. Its customers include Medical Professionals, Patients and Researchers.
HI-Bio: A Biogen Company has a B2B, B2D and B2B2C business model. Its revenue comes from Licensing and Product Sales.
HI-Bio: A Biogen Company has approximately 22 employees.
HI-Bio: A Biogen Company has completed 3 funding rounds, raising a total of $1.37B. The latest funding stage is Acquired.
HI-Bio: A Biogen Company offers: Research and Development, Clinical Trials, Medicine Manufacturing, Early Access Programs, Healthcare Innovation.
Top alternatives and competitors to HI-Bio: A Biogen Company include Connect Biopharma, Alumis, Upstream Bio, NBE-Therapeutics AG, Mabwell. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
HI-Bio: A Biogen Company and Connect Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for HI-Bio: A Biogen Company, https://bouncewatch.com/company/hi-bio, updated 17 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout